OncLive
LightNews LightNews
banner
onclive.bsky.social
OncLive
@onclive.bsky.social
920 followers 140 following 2.4K posts
Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.
Posts Replies Media Videos
onclive.bsky.social
Early Activity With DB-1305/BNT325 Signals Potential Expansion of TROP-2 ADCs in Pretreated Metastatic TNBC @erikahamilton9.bsky.social #oncology #bcsm
www.onclive.com/view/early-a...
Early Activity With DB-1305/BNT325 Signals Potential Expansion of TROP-2 ADCs in Pretreated Metastatic TNBC | OncLive
Erika P. Hamilton, MD, discusses initial efficacy and safety data with the TROP2-targeted ADC DB-1305/BNT325 in pretreated metastatic TNBC.
www.onclive.com
November 10, 2025 at 8:23 PM
onclive.bsky.social
Lutetium Lu 177 Vipivotide Tetraxetan Enables Some Patients with mCRPC to Avoid Chemotherapy #colorectalcancer #oncology

www.onclive.com/view/lutetiu...
Lutetium Lu 177 Vipivotide Tetraxetan Enables Some Patients with mCRPC to Avoid Chemotherapy | OncLive
Daniel J. George, MD, discusses the role of lutetium Lu 177 vipivotide tetraxetan in metastatic CRPC and patient selection considerations.
www.onclive.com
November 10, 2025 at 7:51 PM
onclive.bsky.social
Pharmacists Play Key Role in Patient Education and Treatment Adherence in CML Management #leusm #oncology www.onclive.com/view/pharmac...
Pharmacists Play Key Role in Patient Education and Treatment Adherence in CML Management | OncLive
Jose Tinajero, PharmD, BCOP, discusses the role of the pharmacist in treatment planning and management in chronic myeloid leukemia.
www.onclive.com
November 10, 2025 at 6:09 PM
onclive.bsky.social
@ucsfcancer.bsky.social Urology Clinicians Present Research Findings at #SurgeWest25 #oncology #prostatecancer

www.onclive.com/view/ucsf-ur...
UCSF Urology Clinicians Present Research Findings at SurgeWest 2025 | OncLive
UCSF clinicians present research at SurgeWest 2025, on an RNA biomarker for prostate cancer and opioid prescribing patterns after urologic surgery.
www.onclive.com
November 10, 2025 at 3:28 PM
onclive.bsky.social
Chan Breaks Down the Need for Dose Escalation With Somatostatin Analogs in GEP-NETs @danafarber.bsky.social @harvardmed.bsky.social @nanets.bsky.social #NANETS25 #medtwitter #oncology www.onclive.com/view/chan-br...
Chan Breaks Down the Need for Dose Escalation With Somatostatin Analogs in GEP-NETs | OncLive
Jennifer Chan, MD, MPH, discusses dose escalation and interval shortening with somatostatin analogs for GEP-NETs and how SORENTO may shape treatment.
www.onclive.com
November 8, 2025 at 8:44 PM
onclive.bsky.social
Yale Study Sheds Light on Cellular Resistance to Osimertinib in Adenocarcinoma @yalecancer.bsky.social #oncology
www.onclive.com/view/yale-st...
Yale Study Sheds Light on Cellular Resistance to Osimertinib in Adenocarcinoma | OncLive
Protein METTL7A plays key role in resistance to drugs targeting EGFR-mutant lung adenocarcinoma.
www.onclive.com
November 7, 2025 at 8:28 PM
onclive.bsky.social
Camizestrant Plus CDK4/6 Inhibition Causes Minimal Effect on Visual QOL in HR+, ESR1-Mutated Breast Cancer #oncology #bcsm
www.onclive.com/view/camizes...
Camizestrant Plus CDK4/6 Inhibition Causes Minimal Effect on Visual QOL in HR+, ESR1-Mutated Breast Cancer | OncLive
Use of camizestrant plus a CDK4/6 inhibitor at the emergence of an ESR1 mutation did not significantly worsen visual symptoms in HR-positive breast cancer.
www.onclive.com
November 7, 2025 at 8:21 PM
onclive.bsky.social
Sign up to read insights from @surbhisidanamd.bsky.social & Joshua Richter, MD, about how the @fda.gov approval of BVd is set to reframe R/R myeloma management! @stanfordhealthcare.bsky.social @mountsinainyc.bsky.social #mmsm #hematology
www.onclive.com/view/bvd-app...
November 7, 2025 at 2:03 PM
onclive.bsky.social
BREAKING 🚨: @fda.gov Approves Subcutaneous Daratumumab for High-Risk Smoldering Multiple Myeloma

Read all about it 📰: onclive.com/view/fda-app...

#mmsm #FDAapproved #oncology
November 6, 2025 at 8:12 PM
onclive.bsky.social
Adjuvant Durvalumab Plus Tremelimumab Yields DFS Advantage in Resected RCC @myesmo.bsky.social #ESMO2025 #ESMO25 #kcsm #oncology
www.onclive.com/view/adjuvan...
Adjuvant Durvalumab Plus Tremelimumab Yields DFS Advantage in Resected RCC | OncLive
Treatment with adjuvant durvalumab plus tremelimumab resulted in a DFS benefit vs active monitoring in RCC, particularly in the higher-risk population.
www.onclive.com
November 6, 2025 at 6:02 PM
onclive.bsky.social
UGN-103 Yields High 3-Month CR Rate in Low-Grade, Intermediate-Risk NMIBC #oncology #NMIBC #urothelialcancer
www.onclive.com/view/ugn-103...
UGN-103 Yields High 3-Month CR Rate in Low-Grade, Intermediate-Risk NMIBC | OncLive
UGN-103 produced a 77.8% 3-month CR rate in patients with low-grade, intermediate-risk NMIBC.
www.onclive.com
November 6, 2025 at 4:47 PM
onclive.bsky.social
JAK Inhibitor Selection and Sequencing Strategies Are Key in #Myelofibrosis Management @akritigjain.bsky.social #oncology

www.onclive.com/view/jak-inh...
JAK Inhibitor Selection and Sequencing Strategies Are Key in Myelofibrosis Management | OncLive
Akriti Jain, MD, discusses treatment selection and sequencing of JAK inhibitors in myelofibrosis, emerging CALR-targeted research, and defining disease modification.
www.onclive.com
November 5, 2025 at 8:15 PM
onclive.bsky.social
Sneaky Senescent Cells That Resist Cancer Treatment Can Provide Druggable #LungCancer Target @ucsfcancer.bsky.social #oncology

www.onclive.com/view/sneaky-...
Sneaky Senescent Cells That Resist Cancer Treatment Can Provide Druggable Lung Cancer Target | OncLive
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
www.onclive.com
November 5, 2025 at 6:47 PM
onclive.bsky.social
FDA Grants Orphan Drug Designation to M2T-CD33 for Acute Myeloid #Leukemia #leusm #oncology

www.onclive.com/view/fda-gra...
FDA Grants Orphan Drug Designation to M2T-CD33 for Acute Myeloid Leukemia | OncLive
The FDA has granted orphan drug designation to M2T-CD33 for the treatment of patients with acute myeloid leukemia.
www.onclive.com
November 5, 2025 at 4:37 PM
onclive.bsky.social
HER2DX Could Aid Chemotherapy Decision-Making in Older HER2+ Early-Stage #BreastCancer

www.onclive.com/view/her2dx-...
HER2DX Could Aid Chemotherapy Decision-Making in Older HER2+ Early-Stage Breast Cancer | OncLive
HER2DX low-risk scores were associated with improved 10-year RFS and OS outcomes in older patients with HER2-positive early-stage breast cancer.
www.onclive.com
November 5, 2025 at 4:13 PM
onclive.bsky.social
GEP-NET–Focused Research Refines Optimal PRRT Use in Well-Differentiated Disease #oncology #pancreaticcancer @mskcancercenter.bsky.social
www.onclive.com/view/gep-net...
GEP-NET–Focused Research Refines Optimal PRRT Use in Well-Differentiated Disease | OncLive
Rohit Thummalapalli, MD, discusses the treatment paradigm for patients with GEP-NETs and the role of Lutetium Lu 177 dotatate across lines of therapy.
www.onclive.com
November 5, 2025 at 3:21 PM
onclive.bsky.social
Immune-Modulatory and mRNA-Based #CancerVaccines Could Boost Benefit With ICIs Across #SolidTumors

Watch the full video and read the article here!
www.onclive.com/view/immune-...
Immune-Modulatory and mRNA-Based Cancer Vaccines Could Boost Benefit With ICIs Across Solid Tumors | OncLive
Three experts spotlight key trials from the 2025 ESMO Congress investigating novel cancer vaccines across solid tumors.
www.onclive.com
November 5, 2025 at 2:24 PM
onclive.bsky.social
Positive KEYNOTE-B96 Data Show Role for Immunotherapy–Based Regimens in PROC #oncology #ovariancancer
www.onclive.com/view/positiv...
Positive KEYNOTE-B96 Data Show Role for Immunotherapy–Based Regimens in PROC | OncLive
Nicoletta Colombo, MD, PhD, discusses clinical implications for integrating immunotherapy into the treatment arsenal for platinum-resistant ovarian cancer.
www.onclive.com
November 4, 2025 at 8:16 PM
onclive.bsky.social
FDA Approves Menin Inhibitor for Patients With Acute Leukemia With NPM1 Mutation, Backed by @danafarber.bsky.social Science

www.onclive.com/view/fda-app...
FDA Approves Menin Inhibitor for Patients With Acute Leukemia With NPM1 Mutation, Backed by Dana-Farber Science | OncLive
The US FDA approved revumenib, a first-in-class oral menin inhibitor, for the treatment of adults and children one year and older with relapsed or refractory AML with NPM1 gene mutations.
www.onclive.com
November 4, 2025 at 6:21 PM
onclive.bsky.social
Adjuvant Ribociclib Plus AI Therapy Shows More Pronounced iDFS Benefit After 5 Years in HR+, HER2-Negative Early #BreastCancer #oncology

www.onclive.com/view/adjuvan...
Adjuvant Ribociclib Plus AI Therapy Shows More Pronounced iDFS Benefit After 5 Years in HR+, HER2-Negative Early Breast Cancer | OncLive
Sara A. Hurvitz, MD, FACP, unpacks data with adjuvant ribociclib plus endocrine therapy from the 5-year prespecified analysis of the NATALEE trial.
www.onclive.com
November 4, 2025 at 2:04 PM
onclive.bsky.social
Allogenic CAR T-Cell Therapy CB-011 Drives Responses in R/R #Myeloma #oncology

www.onclive.com/view/allogen...
Allogenic CAR T-Cell Therapy CB-011 Drives Responses in R/R Myeloma | OncLive
CB-011 elicited responses in patients with relapsed/refractory multiple myeloma.
www.onclive.com
November 4, 2025 at 1:25 PM
onclive.bsky.social
Meta Analysis Highlights Benefits of JAK Inhibitors vs BAT in Myelofibrosis @uthealthhouston.bsky.social #hematology #oncology
www.onclive.com/view/meta-an...
Meta Analysis Highlights Benefits of JAK Inhibitors vs BAT in Myelofibrosis | OncLive
Findings from a meta analysis showed that JAK inhibitors were associated with improved outcomes vs best available therapy in myelofibrosis.
www.onclive.com
November 3, 2025 at 8:09 PM
onclive.bsky.social
177Lu-Edotreotide Demonstrates Efficacy and Notable Safety Advantage in Advanced GEP-NETs @vhio.bsky.social @vallhebron.com @myesmo.bsky.social #ESMO25 #ESMO2025 #Oncology
www.onclive.com/view/177lu-e...
177Lu-Edotreotide Demonstrates Efficacy and Notable Safety Advantage in Advanced GEP-NETs | OncLive
Jaume Capdevila, MD, PhD, discusses the potential for 177Lu-edotreotide for the treatment of patients with neuroendocrine tumors.
www.onclive.com
November 3, 2025 at 8:01 PM
onclive.bsky.social
Vorasidenib Sustains Long-Term Benefit in IDH-Mutant Grade 2 Glioma @dgsomucla.bsky.social #btsm #oncology
www.onclive.com/view/vorasid...
Vorasidenib Sustains Long-Term Benefit in IDH-Mutant Grade 2 Glioma | OncLive
Long-term follow-up results show vorasidenib prolongs PFS and reduces tumor progression vs placebo in IDH-mutant grade 2 glioma.
www.onclive.com
November 3, 2025 at 4:06 PM
onclive.bsky.social
OncLive’s October EMA Regulatory Recap: Key EU Approvals in Oncology #EuropeanApprovals #oncology

www.onclive.com/view/onclive...
OncLive’s October EMA Regulatory Recap: Key EU Approvals in Oncology | OncLive
Here is your snapshot of all oncologic therapeutic options that were approved by the EMA in October 2025.
www.onclive.com
November 3, 2025 at 3:14 PM